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Case report
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Tenosynovial giant cell tumors are extremely rare tumors with highly nonspecific symp-
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toms. This benign but aggressive disease has a slow course of progression; however, it can
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ultimately lead to irreversible damage to a joint. Here we describe a case of a 45-year-old
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female with a diagnosis of tenosynovial giant cell tumors of the distal tibiofibular joint, the
second case described in the literature for such location. Appropriate imaging studies and
ultimately histologic studies are necessary for the correct diagnosis. Some locations are par-
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ticularly unusual for these tumors making a high level of suspicion as well as treatment by
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an oncology orthopedic surgery specialist at a high-volume center paramount.
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Introduction
Tenosynovial giant cell tumors (TGCT) were fist described in
1941 by Jaffe and include a group of tumors present usually
in relationship with synovium, bursas or tendon sheaths [1].
In 2013 the World Health Organization re-named this disease from what was formerly being called extra-articular giant cell tumor of tendon sheath and nodular tenosynovitis to
localized TGCT, while what was initially called intra-articular
pigmented villonodular synovitis was-renamed diffuse TGCT
and includes the diffuse-type giant cell tumors [2]. This disease affects most commonly adults between the third and
fourth decade of life but has been known to affect the pediatric population as well [3,4]. Additionally, TGCT demon-

✩

strates a slight predominance for females (60%) [3]. TGCT is
in the vast majority of the cases a monoarticular disease although multijoint affectation has been reported; moreover,
as previously mentioned it can present as a localized nodule or diffusely affecting a joint [5,6]. The prevalence of TGCT
is thought to be of 1.8 cases per million for the diffuse form
and 9.2 per million for the localized form [7]. The localized
form of this disease affects more commonly the hands and
digits, followed by foot and ankle, while the diffuse form involves mainly the knee, followed in frequency by hip, ankle,
and elbow [2,8]. Symptoms are nonspecific which along the
rarity of this disease can cause a significant delay in the diagnosis of these patients [9]. Because this is a slow progressing disease time from initial symptoms to the final histologic diagnosis can vary from a year to 3 years [10]. Patients
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can present with pain, swelling and limitation of the affected
joint as well as repeated episodes of hemarthrosis over time
[9,11].
Here we describe a case of TGCT of the distal tibiofibular
joint, an extremely rare location, managed by surgical resection. To the best of our knowledge this is the second localized
case in such location to be described in literature.

Fig. 1 – Positron emission tomography with computed
tomography. Axial images demonstrating uptake at the
level of the distal tibiofibular joint (∗ ) with a standard
uptake value of 7.9 as well as scalloping of the distal lateral
tibia (arrowhead).

Case report
A 45-year-old female with history of costochondritis, fibrocystic breasts, hypercholesterolemia, and gastroesophageal reflux disease, was referred to our orthopedic oncology clinic
for further evaluation and management of a left ankle le-

Fig. 2 – Magnetic resonance imaging study from August 2020 depicting the lesion in the distal tibiofibular joint (∗ ), the distal
lateral scalloping and posterior invasion into the soft tissues (arrowhead). (A) proton density sequency of 2 axial cuts view
and 1 sagittal, (B) T1 fat suppressed with Gadolinium sequence, 2 axial cuts and 1 sagittal view, (C) short tau inversion
recovery sequence, 2 axial cuts and 1 sagittal cut.
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Fig. 3 – Fluoroscopic images used for guidance during the
biopsy mini-open procedure. A pituitary instrument is
observed within the distal tibiofibular joint.

sion found on recent imaging studies. During the initial visit,
the patient reported left ankle pain which was new and had
been present for 2 months. Patient stated the pain was moderated and controlled by nonsteroidal anti-inflammatories.
Due to her pain, she was unable to exercise and required
the use of a cane for assistance with ambulation. In addition, patient reported recent fatigue. She denied night sweats,
chills, fever, unintentional weight loss, and loss of appetite.
On physical examination, no palpable mass, tenderness, erythema, or swelling over the left ankle were noted. Range
of motion and sensation in the ankle were within normal
limits.
Prior to initial consultation, the patient obtained several
diagnostic imaging studies due to a new mass noted on her
breast. A positron emission tomography with computed tomography scan was obtained (July 2020) and revealed a lesion in the distal tibiofibular joint with fluorodeoxyglucose uptake and a maximum standardized uptake value of 7.9 (Fig. 1).
A decision was made to obtain a contrasted magnetic resonance imaging (MRI) study. The MRI of the left ankle with
and without Gadolinium contrast obtained in August 2020
demonstrated an enhancing 2.2 × 1.8 × 3.5 cm soft tissue
mass at the syndesmosis space corresponding to the area of
hyper-metabolic activity on the positron emission tomography with computed tomography scan (Fig. 2). Small foci of
T1/T2 hypo-intense signal within the mass, a possible reflection of mineralization, was also reported. In addition, the MRI
reported an area of cortical scalloping over the distal lateral
tibia suggesting a chronic nonaggressive process with no abnormal marrow signal or other evidence of osseous infiltration, however overall characteristics of the mass were indeterminate and tissue sampling was recommended to exclude
malignancy.
It was decided to proceed with an open biopsy of the left
ankle mass under fluoroscopic guidance (Fig. 3). A 3 cm incision was made over the distal posterior aspect of the left
lateral malleolus. Dissection was carried down to bone with a
cautery. The fibular tendon and muscle were retracted medially and the posterior aspect of the tibiofibular joint visualized.
A mass with yellowish and brown components was then observed, and samples were obtained for frozen and permanent

pathology analysis (Fig. 4). Pathology report revealed a diagnosis of giant cell tumor of tendon sheath.
Patient was taken to the operating room 3 weeks later for
left ankle tumor resection under fluoroscopic guidance. A 4
cm incision was done over the prior incision over the distal
posterior aspect of the left malleolus. Deep dissection was
carried down bluntly. The fibularis tendons were retracted
distally and the posterior aspect of the tibiofibular joint was
accessed. The TGCT was identified, marginally resected, and
sent to pathology for analysis. Pathology report revealed mass
to be synovial tissue with nodular hyperplasia with pigment
deposition consistent with TGCT (Fig. 5).
Patient is currently 3 months post tumor resection with
completely resolution of her ankle symptoms. Patient was recommended physical therapy and will continue surveillance
studies with a new contrasted MRI in 6 months.

Discussion
TGCT are a group of benign tumors and although the disease
tends to be slow growing it can potentially damage a joint
and severely affect the quality of life of these patients [9,10].
The disease usually presents in young adults with highly
nonspecific symptoms which leads to the diagnosis oftentimes being delayed for years. The etiology of this disease
is not known though the mechanism by which it damages
the joints has been identified [12,13]. There is an uncontrollable proliferation of the synovium (villonodular proliferation),
hemosiderin deposits which causes the pigmentation seen in
our mass (Fig. 4), the tumor cells attract an inflammatory infiltrate with mononuclear and multinuclear osteoclast-giant
cells that along with the repetitive episodes of hemarthrosis
are thought to be responsible for the joint damage [14,15].
On radiographs this disease can present as a joint effusion
as well as bone erosion; with rare but described calcifications
within the tumor [16,17]. The bone lesions present a sclerotic
margin and are usually present in both sides of the joint [16].
As with most tumors the preferred imaging study is an MRI
with and without contrast. There TGCT is depicted as a localized or diffuse mass with heterogeneous low signal intensity on T1 and T2-sequences that enhances with Gadolinium.
Blooming effect is also usually observed due to the magnetic
effect the iron within the hemosiderin deposits causes [18].
Some areas with low hemosiderin concentration can also display a high intensity on T1 and T2 sequences, but the classical image is the one of a mass low in T1 and T2 sequences
[18]. More recently PET-CT scans have also been used to study
TGCT and also to assess treatment effect when a systemic
modality of treatment is chosen [19]. TGCT lesions present
with significant uptake and can have a mean standardized uptake value of 8.7 behaving as hypermetabolic tumors, a characteristic that can mislead radiologists towards a malignant
diagnosis such as sarcoma or metastatic disease [20,21].
On histopathology analysis TGCT present as a combination in variable proportions of small histiocytes, mononuclear
cells with eccentrical nuclei, eosinophilic cytoplasm, and a peripheral rim of hemosiderin, osteoclasts-like giant cells, xanthomatous (foamy) macrophages, lymphocytes, and plasma
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Fig. 4 – Gross image of the sample obtained for pathology analysis during the biopsy. A mass with yellowish and brown
areas is seen. (Color version of figure is available online.)

Fig. 5 – Histopathological analysis of the left ankle mass resection. (A) low power view of the mass depicting sheets of cells
of infiltrative nature and a dense stroma (H&E, 10x), (B) Dense small mononuclear cell stroma (H&E, 10x), (C) Mononuclear
cell stroma and osteoclast-like multinucleated giant cells (H&E, 20x), (D) Giant cells in more detail, histocytes and foam cells
(H&E, 20x).

cells [22]. Due to this common facade of an inflammatory infiltrate, there was an initial thought that there was an inflammatory component to the nature of this disease, leading some
to claim it was an inflammatory process such as rheumatoid
arthritis, but a clonal mutation was identified which allowed
to confirm the tumoral nature of this lesion [23,24]. A specific translocation involving chromosomes 1 and 2, causing

the overexpression of colony-stimulating factor 1 (CSF1) was
identified in 2006 as critical for development of this disease
[24]. The augmented CSF1 expression is only found in 2%-16%
of the cells, the remaining cells being the nonspecific inflammatory infiltrate previously described. These inflammatory
cells are attracted due to a receptor that responds to the overexpressed factor (CSF1R) [24]. Currently available treatment
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options target this receptor to address TGCT, when resection
is not indicated [25].
Treatment for TGCT is predominantly surgical, with excision of the tumor. Depending on the location and the extent
of disease, the procedure may be done open or arthroscopically. The rate of recurrence for this disease is high, 14%-40%,
which causes patients to undergo several surgical procedures,
future joint replacements, decreased range of motion and low
quality of life [26,27]. Radiation therapy has been advocated as
an option to decrease recurrence in diffuse TGCT however is
not free of complications such as joint stiffness, osteoarthritis, osteonecrosis, and malignant transformation or secondary
radiation induced sarcomas [28].

Conclusion
TGCT are benign but aggressive soft tissue tumors with highly
nonspecific symptoms at presentation. Some locations such
as the distal tibiofibular joint are particularly unusual and a
high level of suspicion as well as the correct imaging studies
are paramount for the correct diagnosis of this rare disease as
it could be confused with a degenerative cyst. These tumors
although slow growing have the potential to irreversibly damage a joint, making appropriate diagnosis and treatment by an
oncology orthopedic surgery specialist at a high-volume center of the utmost importance.

Patient Consent
Per the local Institutional Review Board consent was exempt
due to this being the case of research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimen with the information
being recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked
to the subjects.
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